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Early infectionlish latent infection in CD4+ lymphocytes represents a major barrier to the
eradication of HIV. It is not clear what mechanisms favor latent over productive infection, but prior studies
have suggested a role for the viral transcription factor Tat or its RNA target, TAR. Using samples from ﬁve
individuals who were started on ART within 6 months of infection and achieved a viral load b50
(suppressed), we isolated one- and two-exon tat RNA from HIV propagated ex vivo from baseline plasma and
from co-cultures of CD4+ T cells obtained at baseline and suppressed time points. Compared to virus from
the baseline plasma (mostly from productively-infected CD4+ T cells), virus from the baseline and
suppressed co-cultures (mostly from latently-infected cells) had more Tat variants with impaired
transactivation activity. These ﬁndings suggest that impaired activity in the Tat–TAR axis may contribute
to the establishment of latent infection in CD4+ T cells.
© 2009 Elsevier Inc. All rights reserved.Introduction
HIV-1 can establish a latent infection in resting CD4+ T cells
(Chun et al., 1997; Chun et al., 1995), and these latently infected cells
are a major obstacle to the eradication of HIV (Finzi et al., 1999;
Ramratnam et al., 2000; Siliciano et al., 2003; Strain et al., 2003;
Wong et al., 1997; Zhang et al., 1999). These cells harbor integrated
HIV provirus and do not produce virus constitutively, but can be
induced to produce replication-competent virus upon activation.
Latently-infected CD4+ T cells have been found in low numbers in all
HIV+ patients (Chun et al., 1997). The prolonged half-life of the
latent reservoir led to the suggestion that HIV cannot be eradicated
by conventional antiretroviral therapy (ART) alone (Finzi et al., 1999;
Ramratnam et al., 2000; Siliciano et al., 2003; Strain et al., 2003;
Wong et al., 1997; Zhang et al., 1999). Latency also results in archivingph.wong2@va.gov (J.K. Wong)
ll rights reserved.of HIV variants with drug resistance mutations, compromising the
effectiveness of ART (Martinez-Picado et al., 2000).
It is not clear what determines whether an infected cell will
progress to productive or latent infection. Though multiple different
mechanisms may contribute to latency (reviewed in (Marcello,
2006)), considerable research has focused on the viral transcription
factor Tat (the Trans-activator of transcription) (Arya et al., 1985;
Sodroski et al., 1985) and its RNA target, TAR (the Trans-Activation
Response region) (Berkhout et al., 1989). Tat, a viral protein encoded
by two exons, has been shown to stimulate transcription in a trans
fashion. During HIV replication, Tat binds to a stem–loop region of the
nascent RNA (TAR) and the cellular cofactor PTEF-b (Positive
Transcription Elongation Factor B), leading to phosphorylation of
RNA polymerase II and reversing a block to transcriptional elongation
(Isel and Karn, 1999; Kao et al., 1987). In the absence of Tat, the arrest
in transcriptional elongation results in short, prematurely terminated
transcripts (Kao et al., 1987).
Indirect evidence suggests that latency could be due to impaired
activity in the Tat–TAR axis. This evidence includes: 1) the presence of
Table 1
Clinical characteristics of the study subjects
Individual Peak VL Baseline
CD4/%
Baseline
VL
Suppressed
CD 4/%
Suppressed
VL
Regimen
A046 268,145 304/NA 268,145 349/NA b50 AZT, 3TC, ABC
A047 907,400 497/40.9 907,400 738/47.6 b50 AZT, 3TC, ABC
A048 156,852 474/30 15,976 538/30 b50 D4T, 3TC, ABC,
APV/RTV
A049 2,464,790 528/22 47,438 620/43 b50 D4T, 3TC, ABC,
APV/RTV
A050 195,568 542/16 118,891 497/29 b50 AZT, 3TC, IDV/
RTV
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1998; Emiliani et al., 1996); 2) the presence of short, prematurely-
terminated RNA transcripts in latently-infected patient cells (Adams
et al., 1994; Kao et al., 1987; Lassen et al., 2004a; Lin et al., 2003); and
3) the ability of exogenous Tat to rescue viral expression from latently-
infected cells (Adams et al., 1994; Lin et al., 2003; Sonza et al., 2002).
However, few if any studies have sought to systematicallymeasure the
range of activities in Tat/TAR cloned directly from patient samples,
especially from latently-infected cells. In both the SIV macaque model
of pathogenic lentiviral infection and in some human studies, it has
been noted that regulatory and accessory genes, including tat and nef,
are among the earliest to diversify under host immune selection
(Addo et al., 2001; Allen et al., 2000; Cao et al., 2003). We
hypothesized that natural variation in tat sequence would accumulate
soon after primary HIV infection, that sequence variation would lead
to a corresponding variation in Tat-mediated transcriptional activity
(transactivation), and that latent HIV would be enriched for Tat/TAR
variants with impaired transactivation activity.
Despite circumstantial and in vitro data pointing to the role of
attenuated Tat activity in latency, testing this hypothesis in patient
samples is complicated by the large proportion of replication-
incompetent genomes that would be represented by direct PCR
ampliﬁcation from clinical samples (Meyerhans et al., 1989) and by
the potential for selection against impaired Tat activity during cell
culture procedures that are necessary to demonstrate replication-
competence. Tominimize sampling themany replication-incompetent
forms that collect in peripheral blood mononuclear cells (PBMC)
over longer periods of infection (Sanchez et al., 1997), we chose to
study individuals initiating treatment soon after infection and to
isolate tat RNA from replication-competent virus that was success-
fully propagating in culture.
Samples were obtained from ﬁve individuals with acute or early
infection who were started on combined ART and subsequently had
decrease in VL to b50 copies/ml (herein referred to as suppressed).
Plasma was obtained before therapy (baseline). CD4+ T cells were
isolated at both baseline and suppressed time points. Since N95% of
the plasma virus in an untreated patient comes from productively-
infected cells (Ho et al., 1995; Perelson et al., 1997a, 1997b; Perelson et
al., 1996; Wei et al., 1995; Wodarz and Nowak, 2002), virus from the
baseline plasma should be predominantly non-latent virus. Replica-
tion-competent, latent virus was obtained by activating CD4+ T cells
from suppressed time points and co-culturing them with activated
CD8-depleted peripheral blood lymphocytes (PBL) from healthy
donors (“suppressed co-cultures”). Given that the plasma virus at
these time points is undetectable, most virus recovered from these co-
cultures should represent latent virus that has been “rescued” by
activation and provision of susceptible donor target cells. Virus from
nonsuppressed (baseline) co-cultures should also come mostly from
latently-infected cells, as suggested by previous in situ hybridization
studies on activated and non-activated PBMC from untreated patients
(Derdeyn et al., 1999).
We generated one and two exon tat cDNA from RNA extracted
from baseline plasma, from baseline plasma spinoculated onto donor
CD8-depleted PBL, and from co-cultures obtained from CD4+ T cells
at baseline and suppressed time points. We also isolated the trans-
activation response region (TAR) from co-cultures obtained at base-
line and after suppression. Tat-mediated transcriptional activity
(transactivation) was measured by transfection of equal amounts of
DNA into reporter TZM-bl or LuSIV cells expressing luciferase under
control of the HIV or SIV LTR.
Tat/TAR sequences and Tat function from the baseline plasma
(representing predominantly non-latent virus) were compared to
those from the baseline and suppressed co-cultures (predominantly
latent virus). We found that genotypic variation in tat and TAR
sequence accumulated early in infection. The Tat variants exhibited a
range of transactivation activities, both within and between indivi-duals, including a number with reduced transactivation activities.
There were more Tat alleles with impaired activity in the co-cultures
than in the baseline plasma, and the Tat alleles from the co-cultures
were on average more impaired than those from the baseline plasma,
suggesting that variability in Tat function can contribute to the
establishment of latent infection with HIV-1.
Results
Clinical data
The baseline (pretherapy) samples from the ﬁve study participants
(Strain et al., 2005) showed a mean CD4 cell count of 469 cells/μl
(range: 304 to 542) and a mean VL of 271,570 copies/ml (range:
15,976 to 907,400) (Table 1). After initiation of ART, all subjects had a
decrease in VL to b50 copies/ml. When blood was drawn for the
suppressed time points (after 1 to 3.5 months of suppression), the
mean CD4 count had increased to 548 cells/μl (range: 349 to 632).
Spinoculation and culture of baseline plasma virus
Spinoculation of the baseline plasma was successful for 3 of 5
individuals (A046, A047, and A049). For A047, A049, and positive
control, rising p24 was detected at days 3–6. Virus from A046 grew
more slowly, with rise in p24 detected at days 11–14 and a lower peak
p24 (data not shown).
Tat and TAR clones
229 tat clones were isolated (range: 21 to 62 per individual),
including 143 two-exon tat clones and 86 one-exon tat clones. Of
these 229 clones, there were 58 from baseline plasma (27 from direct
extraction and 31 from spinoculation), 73 from baseline co-cultures,
and 98 from suppressed co-cultures. We also isolated a total of 116
TAR clones from baseline or suppressed co-cultures.
Tat sequences showed patient speciﬁc phylogenetic clustering and
variable sequence diversity
Maximum likelihood phylogenetic treeswere constructed using the
ﬁrst exon tat sequences (Supplementary Fig. 1) and TAR sequences
(Supplementary Fig. 2). Separate phylogenies were created for two-
exon tat sequences (Fig. 1) and for one exon tat sequences from each
individual. Fig. 2 shows a tree for one representative individual, A047.
Both tat and TAR sequences from all 5 individuals formed patient-
speciﬁc clusters that were distinct from each other and from the lab
strains HXB2 andNL4-3. For a given individual, therewas intermingling
of taxa representing clones frombaseline plasmas, baseline co-cultures,
and suppressed co-cultures.
For the ﬁve individuals included in this study, mean genetic
diversity of Tat during primary infection ranged from 0.2% to 1.0%.
38.2% of Tat clones from the ﬁve study subjects had one ormore amino
acid change(s) relative to the corresponding consensus sequence. The
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baseline co-cultures, and 34.7% in the suppressed co-cultures.
Cloning of NL4-3 tat
Of 22 different clones of NL4-3, therewere a total of ﬁve amino acid
substitutions (4 missense and 1 stop codon) in four clones (18.2%
mutants). Two of the four mutants, corresponding to two of twenty
evaluable NL4-3 clones (10%), had impaired transactivation activity.
Assays for transactivation activity with both TZM-bl cells and LuSIV cells
demonstrated a good dose response relationship
For all expressible tat variants (those cloned into the expression
vector in the correct orientation), transactivation activity was
measured by transfection of equal amounts of DNA into reporter
TZM-bl cells. GFP was used to control for transfection efﬁciency. The
number of GFP positive cells was similar between wells (data not
shown). Fig. 3a shows a dose response curve for transfection of two-
exon NL4-3 Tat into TZM-bl cells. The curve is sigmoidal, with a linear
portion at around 0.1 μg and saturation at higher doses. The detection
limit is about 0.01 to 0.02 μg, with a log linear range from 0.075 to
0.5 μg. Dose response studies using a luciferin substrate showed
similarly shaped curves, albeit with much lower luminescence (data
not shown). For a select number of alleles, transactivation activity was
also measured by nucleofection of equal amounts of DNA into the T
cell line LuSIV. Fig. 3b shows a dose response curve for nucleofection
of two-exon NL4-3 Tat into LuSIV cells. The lower limit of detection is
0.1–0.25 μg, and the curve is linear over a wide range of DNA
concentrations from 0.1 to 5 μg.
Tat variants with impaired activity were present in all sample types but
were signiﬁcantly enriched in those corresponding to latent virus
(co-culture samples)
All ﬁve study participants had Tat variants with impaired
functional activity. The average percentage of clones with reduced
transactivation activity was 13.9% in the baseline plasma, 43.3% in the
baseline co-cultures (p=0.023 for comparisonwith baseline plasma),
and 21.5% in the suppressed co-cultures (p=NS). Many of these were
missense mutations, though there were a number of variants that
appeared to have arisen from abnormal splicing and/or deletion. Figs.
4a–c show the transactivation activities for NL4-3 Tat and selected
two-exon Tat variants (all obtained using the same primers) from each
of three different individuals. The Tat variants exhibited a range of
activities relative to the consensus sequence (the most common
sequence for that individual) and relative to NL4-3. A separate
comparison of consensus one and two-exon Tats from different
individuals revealed considerable variability in Tat activities between
individuals (Fig. 5).
The vast majority of mutations resulted in impaired Tat activity,
though a few mutations (found exclusively in the baseline plasma)
resulted in activities greater than that of the consensus sequence.
Table 2 shows a list of some of the variants with one or two missense
mutations and their fractional activities relative to that of the
corresponding consensus sequence when tested in TZM-bl cells.
When a subset of these alleles was tested in LuSIV cells, the order of
Tat activities was the same, although the actual magnitudes differed.Fig. 1. Phylogenetic tree for two-exon tat sequences. Prematurely-truncated clones
were excluded from analysis. The ﬁrst two digits of each clone name identify the subject
fromwhich that clone was isolated. Scale bar shows genetic distance. The dot after each
clone name indicates the type of sample from which that Tat was cloned. Black dots
indicate clones from spinoculated baseline plasma (note that spinoculation was not
successful for subjects A048 and A050). Grey dots indicate clones from baseline co-
cultures, while white dots indicate clones from suppressed co-cultures. Each increment
on the scale bar represents 1% genetic distance.
Fig. 2. Phylogenetic tree for one-exon tat from subject A047. Prematurely truncated clones and second exon sequences were excluded from analysis. Scale bar shows genetic distance.
Black dots indicate clones from baseline plasma. Grey dots indicate clones from baseline co-cultures, while white dots indicate clones from suppressed co-cultures. Each increment on
the scale bar represents 1% genetic distance.
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Fig. 3. (a, b) Dose response curves for transfection of two-exon NL4-3 Tat. (a) Dose
response curve for transfection of NL4-3 Tat in TZM-bl cells. Reporter TZM-bl cells
containing an integrated LTR linked to beta-galactosidase and luciferase were
transfected with empty vector or 0.001 to 1.5 μg of Tat from NL4-3. After 3 days, cells
were lysed with Beta-Glo (luciferin-galactoside) and the luminescence was read at
30 min. The x axis shows the dose transfected. The y axis shows absolute luminescence.
Error bars show the standard error of measurement (SEM) of two replicate wells. The
data are representative of 2–3 separate experiments. (b) Dose response curve for
transfection of LuSIV cells. LuSIV cells containing an integrated LTR-luciferase were
nucleofected with empty vector or 0.1 to 5 μg of NL4-3 Tat 101. After 3 days, cells were
pelleted and lysed with Bright-Glo (luciferin) and the luminescence was read at 5 min.
The x axis shows the dose transfected. The y axis shows luminescence. Error bars show
the SEM.
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showed even greater impairment in LuSIV cells. For example, the
mutations P10S, W11R, and Y47H from A049 had relative tat activities
of 51.4%, 12.0%, and 62.1% (respectively) in TZM cells, compared to
2.2%, 1.7%, and 5.9% (respectively) in LuSIV cells.
Most clones from the baseline plasma had normal (consensus) or
greater activity, and relatively few (8 clones in 4 subjects) had
impaired activity. No clones from the co-cultures (baseline or
suppressed) had activity greater than that of the consensus sequence,
and while many had consensus sequence and activity, a number of
clones from both co-cultures showed impaired Tat activity. For one
individual (A046), all of the Tat clones from the suppressed co-culture
had consensus sequence, although the majority (6 of 7) of evaluable
clones from the baseline co-culture from this same individual had
substantially impaired activity.
For all ﬁve individuals, the mean Tat activities from the suppressed
co-cultures were less than the mean Tat activities from the baseline
plasmas (p=0.019 by the t test for correlated samples; p=0.05 by
the pairedWilcoxon rank sum test, which is as high as can be achieved
with this test using ﬁve paired samples). The mean Tat activities from
the baseline co-cultures were also less than the mean Tat activities
from the baseline plasmas, though the results were not statistically
signiﬁcant.
For each of the three types of samples (baseline plasma, baseline
co-culture, and suppressed co-culture), we also calculated the mean
(across ﬁve subjects) proportion of Tat sequences with less than orgreater than 90%, 75%, 50%, and 25% of consensus Tat activity (Fig. 6).
Compared to the baseline plasma (black bars), the suppressed co-
cultures (white bars) had a larger proportion of clones with b90%
activity (p=0.039 using the t test for correlated samples; Fig. 6a) and
a trend towards more clones with b75% activity (p=0.077; Fig. 6b).
The baseline co-cultures (grey bars) appeared to have an even larger
proportion of clones with impaired activity, though comparison to the
baseline plasma yielded p values of 0.052 (for b90% activity) and
0.070 (for b75% activity). Compared to the baseline plasma, both co-
cultures also had a trend towards more clones with b50% and b25%
activity.
For each of the three types of samples, we also examined the
relationship between genetic variation in tat (as measured by mean
pairwise genetic distance) and frequency of impaired alleles. There
was no correlation between the two variables (R2=0.0147; p=0.49,
Spearman's Rank Test), suggesting that the increased prevalence of
impaired Tats in the co-cultures (especially baseline co-cultures) is
not merely a reﬂection of increased genetic diversity in those samples,
but instead represents the speciﬁc enrichment of attenuated alleles in
the latent reservoir.
Discussion
In this study, we surveyed the range of Tat/TAR sequences in early
infection to investigate whether impaired activity in the Tat–TAR axis
contributes to the establishment of latent infection in vivo. In ﬁve
individuals with acute or early infection, we found evidence of
considerable variation in Tat sequence and in Tat-mediated transcrip-
tional activity. These ﬁndings concur with previously published
observations that Tat is among the earliest of genes to diversify
under immune selection (Addo et al., 2001; Allen et al., 2000; Cao
et al., 2003; Guillon et al., 2006). In functional assays using reporter
cell lines with wild-type TAR, we found that all subjects had a number
of Tat variants with impaired activity (ranging from 0 to 99%), while
two subjects had Tat variants with increased activity (the latter was
seen in the baseline plasma but not in the co-cultures). Compared to
virus from the baseline plasma (mostly from productively-infected
cells), virus from the suppressed co-cultures (representing mostly
latent virus) had more Tat alleles with impaired (b90%) activity, and
the average Tat activity from the suppressed co-cultures was lower
than that from the baseline plasma. These ﬁndings suggest that
naturally occurring variation in Tat transactivation activity affects the
complex host/viral interactions that control the balance between
productive and latent infection, and that attenuated Tat alleles may
favor latent infection.
Virus from baseline co-cultures also had more impaired Tat alleles
than virus from baseline plasma. These baseline co-cultures could
represent a mixture of productively-infected and latently-infected
cells. However, in situ hybridization studies (Derdeyn et al., 1999) of
PBMC from untreated patients show that the proportion of cells that
can be induced by activation to transcribe HIV RNA greatly exceeds the
proportion that are HIV RNA+ in the absence of activation, suggesting
that even in the untreated patient, the majority of the virus in PBMC is
actually in the form of latent, inducible virus. This conclusion is also in
keeping with the observation that activated lymphocytes which
support productive HIV infection express homing and adhesion
molecules that cause their recruitment and retention in lymphoid
tissues and effector sites. Taken together, these observations suggest
that while the virus from both baseline and suppressed co-cultures
could represent amixture of latent and non-latent virus, latent virus is
likely to predominate in both cases.
The ﬁnding of impaired Tat alleles in the baseline co-cultures may
seem discordant from that of Guillon et al, who sequenced Tat from
PBMC-associated RNA from serial samples of four individuals with
untreated early HIV-1 infection (Guillon et al., 2006). They found
evidence of Tat and Rev mutations that appeared to arise from
Fig. 5. Consensus two-exon Tat activities from NL4-3 and the ﬁve subjects. TZM-bl cells
were transfected with 0.1 μg of either empty vector, NL4-3 Tat, or a clone containing the
consensus Tat sequence (the most common sequence for that individual) for each of the
ﬁve individuals (A046, A047, A048, A049, and A050). All Tat clones were obtained using
the same primers. The x axis shows the clone transfected. The ﬁrst two digits of the
clone name indicate the patient from which it was derived. The y axis shows
luminescence (minus the luminescence for cells alone). Error bars show the SEM of two
replicate wells for that experiment.
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not result in signiﬁcant changes in Tat activity. The apparent
discrepancy is likely explained by differences in methodology. For
example, their PBMC had not been activated, so most of the cell-
associated tat RNAwould be expected to come from the small number
of cells that are constitutively expressing full length HIV-1 RNA
transcripts, which are likely to be productively-infected rather than
latently-infected cells.
One limitation of our study is the small number of subjects studied
(dictated solely by the availability of stored samples). These ﬁndings
will have to be conﬁrmed in larger studies with more participants.
There are other caveats that are intrinsic to studies of this kind. All
studies of viral genetics are complicated by the dilemma of whether
sequences ampliﬁed directly frompatientmaterial (plasma or PBL) are
preferable to those obtained from virus isolated in co-culture. While
direct ampliﬁcation obviates some ex vivo selection artifacts, it cannot
distinguish viral variants of greater or lesser importance based on
phenotypic traits. In the current study, we felt it was important to
utilize an experimental design that could distinguish replication-
defective from replication-competent virus by the criteria of spreading
infection based on increasing p24 levels.
Given the time required to culture virus until the p24 is detectable
(to demonstrate replication competence), contamination with even
small numbers of productively-infected cells might allow non-latent
virus to outcompete and outgrow latent virus with impaired Tat
activity. The use of a three NRTI regimen (in two patients) and the
short duration of suppression may have increased the likelihood of
such “contamination” with productively infected cells (though the
half life of these cells on ART is extremely short). We chose not to
perform additional ex vivo manipulation to exclude activated,
productively-infected cells since, as discussed earlier, these cells are
likely in the minority and we cannot exclude the possibility that aFig. 4. (a–c) Transactivation activities for NL4-3 Tat and selected two-exon Tat variants
from individuals A046 (a), A049 (b), and A050 (c). TZM-bl cells were transfected with
0.1 μg of either empty vector, NL4-3 Tat, a clone containing the consensus Tat sequence
(the most common sequence for that individual), or one of several Tat variants. All Tat
clones were obtained using the same primers. The x axis shows the clone transfected.
The y axis shows luminescence (minus the luminescence for cells alone). Error bars
show the SEM of two replicate wells for that experiment. Black bars represent clones
from the baseline plasma, grey bars represent clones from the baseline co-cultures,
and white bars represent clones from the suppressed co-cultures. The data are
representative of 2–4 different experiments.
Table 2
Transactivation activities relative to consensus
Clone Mutation % Consensus Standard deviation
49-102 V4A; K71⁎ 33.8 23.7
46-AH R7G 93.9 6.5
50-84 E9G; K19R; R52Q 7.6 3.1
49-74 P10S 51.4 8.3
49-113 W11R 12.0 3.4
48-115 (K)Q12R 81.4 6.2
50-BH G15R; K19R 2.5 1.9
49-60 (K)R19Q 89.9 27.3
50-80 K19R 64.7 9.0
47-70 K29E 50.1 12.4
49-9 K29R 69.2 14.7
48-36 (F)L32P 2.7 1.2
48-110 C34R 4.9 5.4
49-K F38L 9.8 11.1
47-2 39I 92.1 4.4
47-U 39I; S75P 125.3 12.8
46-4 A42V 2.1 0.1
47-13 I45T 52.0 1.5
49-U Y47H 62.1 5.0
49-13 A58V 65.3 16.4
46-P S62G 123.6 1.1
50-16 S62N 68.3 10.2
47-96 (T)N64D 80.1 19.0
47-R (S)P70S 94.4 5.1
47-TT Q72R 92.3 5.6
48-1 P73H 96.3 29.5
47-8 E86K 65.0 6.1
49-106 E92G 80.2 11.1
47-7 (T)A97T 88.7 5.9
For clone names (far left column), the ﬁrst two digits of each clone name identify the
subject from which that clone was isolated. The mutations (second column from left)
are listed in order of amino acid position within the protein. Letters in parentheses
indicate the amino acid in NL4-3 (in cases where that differed from the subject's
consensus sequence). The relative transactivation activity of each mutant Tat (third
column) was calculated by taking the average luminescence (from two replicates),
subtracting out the average background luminescence (from empty vector), and
dividing by the average background-subtracted luminescence of the Tat allele with the
consensus sequence (most common sequence for that individual) obtained using the
same forward and reverse primers. Results were then averaged over 2–4 separate
experiments. The far right column shows the standard deviation of the averages from
the 2–4 separate experiments.
Fig. 6. (a, b) Mean proportion of clones with relative Tat activity greater than or less
than 90% (a) and 75% (b). For each of the three types of samples (baseline plasma,
baseline co-culture, and suppressed co-culture) from each individual, we calculated the
proportion of tat sequences in that samplewith less than or greater than a given activity
level (90% or 75%) relative to the appropriate consensus sequence. The means of the
proportions for the ﬁve individuals are displayed on the y axis. Black bars represent
clones from the baseline plasma, grey bars represent clones from the baseline co-
cultures, and white bars represent clones from the suppressed co-cultures.
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and ex vivo processing. It should be noted that when patient CD4+ T
cells were cultured without activation, they never resulted in
spreading infection and positive p24, which seems to suggest that
there were not too many productively-infected cells. Even if the
suppressed co-cultures were “contaminated” with productively-
infected cells, these cells would be expected to have wild type Tat,
and the presence of these cells would cause our methods to
underestimate the true contribution of impaired Tat to latency.
It is also possible that some of the cells going into the co-cultures
(especially the baseline co-culture) had unintegrated but replication-
competent genomes (pre-integration latency). However, multiple
studies have shown that, at least in resting CD4+ Tcells, unintegrated
HIV DNA has a very short half life (on the order of days). Thus, in CD4
+ Tcells, most unintegrated HIV (including “pre-integration latency”)
is likely the product of very recent infection. In the untreated patient
(baseline co-cultures), where N95% of the plasma virus comes from
productively-infected cells, one would expect that most of the new
infection of peripheral CD4+ T cells (and hence, the unintegrated HIV
DNA) is also from productively-infected cells, which would be
expected to have wild-type Tat.
Even if all of the virus came from truly latently-infected cells, if a
small number of latently-infected cells had normal Tat sequence and
function, these would be expected to rapidly outcompete those with
impaired Tat activity. Also, the 1–3 week duration of culture
(necessary to detect +p24) allows time for reversion or back-
mutation of impaired Tat alleles back to a more wild-type phenotype.As a result of all of these factors, our experimental design may
underestimate both the fraction of viruses with impaired Tat activity
and the magnitude of impairment.
We tried to choose a duration of co-culture that was long enough
to get spreading infection and detectable, increasing p24 (thus
ensuring that most of the virus is replication competent), but not so
long as to facilitate back-mutation or overgrowth by virus with normal
Tat activity. For this reason, we chose the earliest time point with
positive p24, which was 7 days for most of the baseline co-cultures.
However, the co-cultures from suppressed time points grew more
slowly (whichmay be due to lower inoculums or impairment in a viral
factor such as Tat), so that p24 was usually not detectable until 14–
21 days. If the data seem to suggest that in some cases the baseline co-
cultures have more impaired Tats than the suppressed co-cultures
(though the numbers are not statistically signiﬁcant), it could be that
the longer duration of the suppressed co-culture allowed more time
for back-mutation or overgrowth from wild-type Tat.
In both baseline and suppressed co-cultures, we were able to
detect mutant Tats with impaired activity. Although mutations can
arise in culture or in the cloning process (from PCR to sequencing), the
use of proofreading enzymes and non-nested PCR protocols should
reduce the latter risk. The increased frequency of mutations and
impaired Tats in the patient samples compared to the NL4-3-infected
PBL suggests that many of these mutations did in fact arise in vivo. To
the extent possible (for example, by using the baseline plasma to
infect donor PBL), we tried to ensure similar culture conditions in the
spinoculated baseline plasma, baseline co-culture, and suppressed co-
culture. Mutations introduced by cloning should be equally likely for
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suppressed co-culture). Also, for many mutations, the same mutation
was seen from different PCR reactions or different co-culture wells,
suggesting that they were not introduced by PCR or cloning. Some
wells had several Tat variants, including some that were totally
defective and should not be replication competent. It is likely that
these wells had a mix of viruses (at least one of which was replication
competent), and/or that there was some trans-complementation.
Where it is possible to compare our Tat phenotypes with results of
previously published genotype/phenotype studies, the results
generally agree. For example, we found that the C34R mutant has
virtually no Tat activity, in agreement with prior mutagenesis studies
that suggest that mutation of any of six key Cys residues (including
C34) virtually abolishes Tat activity (Garcia et al., 1988; Kuppuswamy
et al., 1989; Sadaie et al., 1988). We found that the mutation Y47H
reduced activity to 62% that of the wild type 400 bp Tat from A049,
while Verhoef et al. found that two different forms of Y47H mutation
reduced activity to 40–50% that of the wild type 3.1 kb Tat construct
from LAI (Verhoef et al., 1997). In addition, we found that early
truncations and missense mutations in the N-terminal part of the ﬁrst
exon (4 to 42) generally resulted in dramatically reduced transactiva-
tion activity, while mutations in the distal ﬁrst exon and second exon
had considerably less effect. These results match those of prior
mutagenesis studies that implicate the ﬁrst 48 N-terminal amino acid
residues as the key determinants of transactivation activity (Garcia et
al., 1988; Kuppuswamy et al., 1989; Seigel et al., 1986).
Aside from initiation and elongation of transcription, other
functions have been ascribed to Tat, including both pre-integration
and post-transcriptional processes. These other Tat functions were not
assessed in this study. It is possible that Tat variants with lesser
degrees of impairment in transactivation activity have other effects
(for example, on splicing) that may contribute to latency.
While our ﬁndings implicate attenuated Tat transactivation as
one factor in the establishment or maintenance of latency, wild-type
(consensus) Tat was frequently recovered from co-culture samples.
Even though our experimental design should underestimate the true
proportion with impaired Tat activity, it seems likely that latent
infection can occur with wild-type or near wild-type Tat function.
Indeed, both in vitro and in vivo model systems for HIV latency have
been described utilizing wild-type HIV (Brooks et al., 2001; Jordan
et al., 2003), suggesting that additional factors contribute to latency.
These could include many human cellular factors, perhaps associated
with cellular activation or differentiation state, including those that
modulate Tat activities and those that are Tat-independent. For
example, in resting CD4+ T cells, PTEF-b function is very low and is
probably limiting for Tat (Ghose et al., 2001). Variation in viral
factors other than Tat, such as Rev or Nef, could also contribute to
latency (Pomerantz et al., 1992). Aside from blocks at the level of
initiation or elongation of transcription, latency could be due to a
number of post-transcriptional processes, including altered splicing
of mRNA (Pomerantz et al., 1992), a block in export of mRNA from
the nucleus (Lassen et al., 2006), RNA interference (Bennasser et al.,
2005; Huang et al., 2007; Omoto et al., 2004; Weinberg and Morris,
2006), or a combination of mechanisms (Lassen et al., 2004a,
2004b). Given that Tat and Rev both play roles in splicing and other
post-transcriptional processes, mutations in either or both of these
overlapping genes could contribute to altered splicing or a block to
nuclear export.
In summary, the current study supports the proposal that impaired
Tat activity may contribute to latent infection with HIV. The data
presented here suggest that Tat variation develops very early after
infection and that attenuated Tat activity may favor the establishment
of latency. These ﬁndings deserve further study. Even if latent
infection is not always the result of impaired Tat activity, it is possible
that Tat activators could be used to “ﬂush out” HIV from latently-
infected cells, or that inhibitors of Tat could be used to prevent releaseof virus from latently- or productively-infected cells. To facilitate such
strategies, it is important have a better understanding of the range of
Tat activities associated with latent infection.
Materials and methods
Subjects
The study subjects were participants in the Los Angeles and San
Diego primary infection cohort (Strain et al., 2005). These subjects all
had acute or early infection and were started on combined ART
within 6 months of seroconversion. Blood was drawn for labs,
plasma, and CD4+ T cells before initiation of ART and at various time
points after ART. For this study, we looked through the stored
samples and chose all subjects who had the following samples: 1)
unused plasma dating from before the initiation of ART (baseline); 2)
frozen cell pellets from multiple positive co-cultures from baseline;
and 3) frozen cell pellets from at least one time point after the viral
load had fallen to b50 copes/ml. Five subjects (A046 to A050) met
these criteria. All subjects gave written, informed consent in
accordance with local IRB guidelines.
Spinoculation of baseline plasma
A portion of the baseline plasma was used for direct extraction of
viral RNA. To enhance the yield of replication-competent virus,
provide a better comparator for the co-cultures, and isolate spliced
two-exon tat, the remainder of the baseline plasma was used to
inoculate and infect CD8-depleted PBL from healthy donors. This
inoculation was done under conditions of centrifugation (spino-
culation), as prior studies have shown that spinoculation of plasma
results in a high efﬁciency of infection (Harrington et al., 2000;
O'Doherty et al., 2000). PBMC were isolated from buffy coats of two
healthy donors using Ficoll centrifugation, depleted of CD8+ cells
using Dynabeads CD8 (Dynal/Invitrogen), washed, and resuspended
in complete RPMI+10% FBS at 1 million cells/ml. A portion of the
resting CD8-depleted PBMC was activated for 3 days using PHA (3 μg/
ml, Roche) and IL-2 (20 IU/ml, Chiron). After 3 days, the activated
CD8-depleted PBL from the two donors were washed twice and
resuspended in complete RPMI to a ﬁnal concentration of 20 million
cells/ml. 125 μl from each donor (a total of 5 million cells) was
pipetted into each well of a 48 well plate, followed by either 500 μl of
baseline plasma or controls. The 48well plateswere spun at 1200 g for
2 h at room temperature and incubated for 3 h at 37 °C. The cells were
then resuspended,mixedwith4.3ml of complete RPMI (20% FBS)+IL-
2 (20 IU/ml), and transferred to a 6 well plate (day 0). 300 μl was
removed from eachwell, spun to pellet cells, and saved as separate cell
pellet and supernatant. On days 4, 6, 9, 11, 14, 16, 18, and 21, 1 ml was
removed from each well, spun to pellet cells, saved at −80 °C (as
separate cell pellet and supernatant), and replaced with 1 ml of
complete RPMI (20%)+IL-2 (20 IU/ml). On day 7, 1 ml was removed
for sampling and replaced with 1 ml containing 0.75 million freshly
activated CD8-depleted PBL from each of the two healthy donors. The
frozen supernatantswere thawed and assayed for p24 byELISA (Perkin
Elmer). A separate spinoculation experiment was done using mixed,
resting CD8-depleted PBL (ﬁve million cells+1 ml of baseline plasma
in a 24 well plate) followed by washing, activation with PHA (5 μg/ml
for 1 day), washing of PHA, and serial sampling of 2 ml per well.
Co-cultures
At baseline and suppressed time points, blood was used to isolate
CD4+ T cells and establish co-cultures, as described previously (Strain
et al., 2003; Strain et al., 2005; Wong et al., 1997). Brieﬂy, CD4+ T cells
were isolated from each subject using RosetteSep (StemCell Technol-
ogies), stimulated with anti-CD3/CD28 beads (Dynal/Invitrogen), and
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Supernatants were assayed weekly for evidence of increasing p24
production indicative of replication-competent virus. Corresponding
cell pellets were frozen at−80 °C.
For both baseline and suppressed time points, at least 2 (and
usually 3) co-culture wells were used to isolate virus. By terminal
dilution estimates, these wells contained approximately 10 to 33
latently-infected cells. Co-cultures from baseline time points typically
had positive p24 by day 7, and cell pellets from this day were used to
isolate viral RNA. Co-cultures from suppressed time points grewmore
slowly, with p24 often detectable only at day 14 (used for 4 subjects)
or day 21 (used for one subject). When incubated alone, unstimulated
patient CD4+ T cells invariably had negative p24 despite culture for
≥21 days.
Preparation of lab virus stocks and cloning of NL4-3 Tat
To get a series of corresponding tat clones from NL4-3, and to
provide an estimate for the diversity that can be introduced during
cell culture and cloning, tat was cloned from NL4-3-infected donor
PBL. Viral stocks were generated by transfecting the plasmid pNL4-3
(obtained from the NIH AIDS Research Reagent program) into 293T
cells, using the supernatant (harvested at day 3) to infect pooled
donor PBMC, and harvesting the supernatants from the infected PBMC
(pooled from days 7 to 19). These viral stocks were used to infect fresh
door PBL, and total cellular RNA was isolated after 2 days.
RNA extraction
Genomic HIV-1 RNA was isolated from aliquots of baseline plasma
(thawed from −80 °C) using the QIAmpViral RNA Mini Kit (Qiagen)
according to the manufacturer's instructions. Total RNA was isolated
from cell pellets using Trireagent BD (Molecular Research Center) per
the manufacturer's instructions.
cDNA synthesis
Tat- and TAR-speciﬁc cDNA were generated using Transcriptor
reverse transcriptase (Roche) per the manufacturer's protocol with
incubation at 51 °C for 1 h. For Tat-speciﬁc cDNA, we used the reverse
primer 8776 rev cDNA rev (5′-CCTTTCYAAGCCCTGTCTTATTC-3′,
positions 8761–8783 of HXB2, located downstream of the second
exon of rev). For TAR-speciﬁc cDNA, we used the reverse primer TAR R
(5′-GCACTCAAGGCAAGCTTTAT-3′, HXB2 positions 528–547).
PCR for tat and TAR
PCR was done using the high ﬁdelity polymerase Platinum Taq
Hiﬁ (Invitrogen) using total reaction volume of 50 μl with 5 μl of 10×
buffer, 1 μl of 10 mM dNTPs, 4.5 μl of 50 mM MgSO4, 36 μl of H20, 1 μl
(5–10 pmol) of each primer, and 0.5 μl of Platinum Taq Hiﬁ. To
amplify one-exon tat from baseline plasma, we used the primers
5TTOP (5′-CACCATGGAGCCAGTAGATCCTAG-3′, positions 5831–5850,
with leader sequence for TOPO cloning) and R-vpu-Tat (5′-TCATTGC-
CACTGTCTTCTGCTCT-3′, positions 6206–6228). PCR conditions
included 10 pmol of each primers with 95 °C for 5 s, 40 cycles of
(95 °C for 1 s, 58 °C for 1 s, and 72 °C for 1 s), and 72 °C for 10 s. To
amplify two-exon tat from cell pellets (spinoculated baseline plasma
or co-cultures), we used the primers 5TTOP and 3-T-101-rev (5′-
AGAGTAAGTCTCTCAAGCGG-3′, positions 8531–8550 of rev) with
10 pmol of each primer and annealing T of 57 to 61 °C. To amplify
two-exon tat that also contained the full two-exon rev, a separate
PCR was done with the primers 734-xSpl1-4F (5′-GCGGCGACT-
GAATTGG-3′, spanning the splice site from 743 to 5777) and 8706 rev
PCR rev (5′-CTATCTGTCCCCTCAGCTAC-3′, 8688 to 8707) using 5 pmol
of each primer and an annealing Tof 61 °C. To amplify TAR,we used theprimers TAR F (5′-CCTCAGATCCTGCATATAAGC-3′, positions 413–433)
and TAR R (as above) with 10 pmol of each primer and annealing T of
55 °C.
Cloning and sequencing
For cloning of both tat and TAR, the expression vector pcDNA3.1/
V5-His TOPO TA kit (Invitrogen) was used, as speciﬁed by the
manufacturer. Plasmid preps were done using QIAprep Spin Miniprep
columns (Qiagen) or QIAﬁlter Plasmid Maxi columns (Qiagen). DNA
concentrations were determined using the average of at least two
measurements obtained on a ND-1000 Spectrophotometer (Nano-
Drop). Sequencing was done using a 3130xl Genetic Analyzer (ABI).
Phylogenetic analysis
Initialmultiple sequence alignmentswere generated usingMultalin
with default gap parameters and the DNA 5-0 substitution matrix.
Subsequent manual aligning was performed using the Se-Al sequence
alignment editor. Amaster phylogeny, including sequence data from all
subjects and common lab strains, was created using Dnadist and
Neighbor within the PHYLIP 3.6 software suite (Felsenstein, 1993) to
check for sequence contamination. Maximum likelihood phylogenies
describing sequences from each individual host were built using the
HyPhy software package (Pond et al., 2005) implementing the HKY85
model of sequence evolution and the UPGMA (Unweighted Pair Group
Method with Arithmetic Mean) Clustering Method. All diversity and
divergence measurements were calculated using pairwise maximum
likelihood estimation (MLE). Genbank accession numbers for all
sequences in this manuscript will be provided upon acceptance.
Assessment of transactivation activity
Transactivation activity was measured by transfection of equal
amounts of DNA into reporter TZM-bl cells (generous gift of Drs. John
Kappes and Xiaoyun Wu) obtained through the NIH AIDS Research
Reagent program (Derdeyn et al., 2000; Roos et al., 2000; Wei et al.,
2002). These cells have an integrated HIV-1 LTR driving expression of
β-galactosidase and luciferase.
Each Tat variant was tested in TZM-bl cells in at least two
experiments with two replicates. Each well of a 24-well plate was
seeded with 300,000 TZM-bl cells in 1 ml of DMEM. TZM-bl cells were
transfected using Lipofectamine 2000 (Invitrogen) per the manu-
facturer's protocol. A GFP-encoding plasmid (pCMV-GFP) was co-
transfected to control for transfection efﬁciency. To each well with
400 μl OPTI-MEMmediaweadded100 μl ofOPTI-MEMcontaining2.5 μl
of lipofectamine (frommix), 0.3 μg of GFP (frommix), and 0.1 μg of tat
DNA.Mediumwas changed toDMEMafter 5–6h. On the third day post-
transfection, ﬂuorescence microscopy was done to look for GFP,
medium was removed, and cells were lysed with Beta-Glo (Promega),
which contains a luciferin-galactoside substrate. Luminescence was
measured at 30 min using a Victor 3 luminometer (Perkin Elmer).
For a subset of variants, the transactivation activities were also
measured in a T-lymphocyte derived cell line, LuSIV (a derivative of
the CEM cell line with a reporter luciferase under control of an
integrated LTR), obtained from the NIH AIDS Research Reagent
Program (generous gift of Drs. Jason Roos and Janice Clements)
(Roos et al., 2000). LuSIV cells were transfected using a Nucleofector II
(Amaxa Biosystems) with 1 million LuSIV cells per cuvette, 1 μg of
DNA, and nucleofection program A-020. After 2 days, cells were
pelleted and lysed with Bright-Glo (Promega). Luminescence was
measured at 5 min using the Victor 3 luminometer.
The relative transactivation activity of each mutant Tat was
calculated by taking the average luminescence (from two replicates),
subtracting the average background luminescence (from empty
vector), and normalizing to the background-subtracted luminescence
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sequence for that individual) obtained using the same forward and
reverse primers. Results were then averaged over at least 2–4 separate
experiments. In a separate analysis, the relative activity of each
mutant was compared by normalizing to the activity of NL4-3 Tat
obtained with the same primers from NL4-3-infected PBL cultures.
Given that spinoculationwas successful in only three subjects, the Tats
from spinoculation of the baseline plasma were grouped with those
obtained by direct extraction of the baseline plasma.
Statistics
The mean transactivation activities (normalized to the appropriate
consensus sequence for each individual) from the baseline plasma
(mostly non-latent virus) were separately compared to those from the
baseline and suppressed co-cultures (mostly latent virus) using the
pairedWilcoxon ranked sum test and the t test for correlated samples.
In addition, we calculated the proportion of Tat alleles with less than a
given percentage (25%, 50%, 75%, or 90%) of consensus Tat activity.
Results from baseline plasmas were compared to those from baseline
or suppressed co-cultures using the paired Wilcoxon ranked sum test
and the t test for correlated samples.
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